论文部分内容阅读
①目的了解原癌基因Ｃ－ｅｒｂＢ－２蛋白产物在肝细胞癌发生过程中的表达及其关系。②方法应用抗原癌基因Ｃ－ｅｒｂＢ－２蛋白产物的抗体，检测４１例人肝细胞癌（１８例有癌周组织）的抗原表达。③结果Ｃ－ｅｒｂＢ－２在肝细胞癌及癌周增生结节中的阳性表达率分别为２６．８３％（１１／４１）和２８．５７％（４／１４），两者间差异无显著性（χ２＝０．０２，Ｐ＞０．０５），但两种均高于肝硬变组织（χ２＝４．０２，Ｐ＜０．０５，直接概率计算，Ｐ＝０．０３）。癌周肝硬变组织Ｃ－ｅｒｂＢ－２表达阴性。④结论Ｃ－ｅｒｂＢ－２基因的活化与人肝癌发生有关，且Ｃ－ｅｒｂＢ－２过度表达是肝癌发生过程中的早期表现。同时也证实了增生结节属癌前期病变，与肝癌的发生有关；肝硬变与肝癌的发生没有直接关系。
Objective To understand the expression and relationship of proto-oncogene C-erbB-2 protein product in hepatocellular carcinoma. 2 Methods Anti-cancer antibody C-erbB-2 protein antibody was used to detect the antigen expression of 41 human hepatocellular carcinoma (18 cases with pericancerous tissue). 3 Results The positive expression rates of C-erbB-2 in hepatocellular carcinoma and pericancerous nodules were 26.83% (11/41) and 28.57% (4/14), respectively. There was no significant difference between the two groups. Sex (χ2=0.02, P>0.05), but both were higher than cirrhosis (χ2=4.02, P<0.05, direct probability calculation, P=0.03). C-erbB-2 expression was negative in the cancerous cirrhosis. 4 Conclusion The activation of C-erbB-2 gene is related to the occurrence of human hepatocellular carcinoma, and the overexpression of C-erbB-2 is an early manifestation of liver cancer. It was also confirmed that the proliferative nodule was a precancerous lesion and was related to the occurrence of liver cancer. Liver cirrhosis was not directly related to the occurrence of liver cancer.